c.9253-6T > c REV3L: A novel marker of poor prognosis in Myelodysplastic syndrome
Open Access
- 27 June 2020
- journal article
- research article
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 43 (3) , 377-381
Abstract
No abstract availableKeywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (420501/2018-5, 424542/2016-1)
This publication has 11 references indexed in Scilit:
- The Polymerase Activity of Mammalian DNA Pol ζ Is Specifically Required for Cell and Embryonic ViabilityPLOS Genetics, 2016
- De novo mutations in PLXND1 and REV3L cause Möbius syndromeNature Communications, 2015
- Clinical and biological implications of driver mutations in myelodysplastic syndromesBlood, 2013
- Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroupsBlood Cancer Journal, 2013
- DNA damage tolerance: a double-edged sword guarding the genome2013
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesNew England Journal of Medicine, 2011
- DNA polymerases and cancerNature Reviews Cancer, 2011
- DNA Damage, Aging, and CancerNew England Journal of Medicine, 2009
- Eukaryotic Translesion Polymerases and Their Roles and Regulation in DNA Damage ToleranceMicrobiology and Molecular Biology Reviews, 2009
- DNA polymerase zeta (pol ζ) in higher eukaryotesCell Research, 2007